ArticleSmall methods2019
Exploiting Nanomaterial-mediated Autophagy for Cancer Therapy.
Article in Small methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Enhancing Anticancer Effects: Targeted Doxorubicin Delivery Using UiO-66-NHJournal of materials science. Materials in medicine · 2025Article
- Rationally designed anti-autophagy nanosystems for reversing the immunosuppressive network in the tumor environment.Nanomedicine (London, England) · 2025Article
- Nanotherapeutics targeting autophagy regulation for improved cancer therapy.Acta pharmaceutica Sinica. B · 2024Review
- Review
- The impact of nanomaterials on autophagy across health and disease conditions.Cellular and molecular life sciences : CMLS · 2024Review
- Selective autophagy in cancer: mechanisms, therapeutic implications, and future perspectives.Molecular cancer · 2024Review
- Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Reductive damage induced autophagy inhibition for tumor therapy.Nano research · 2023Article
- Procyanidins and Their Therapeutic Potential against Oral Diseases.Molecules (Basel, Switzerland) · 2022Review
- New Advances in Nano-Drug Delivery Systems:Frontiers in oncology · 2022Review
- Bioresponsive Nanomaterials: Recent Advances in Cancer Multimodal Imaging and Imaging-Guided Therapy.Frontiers in chemistry · 2022Review
- Chiral nanomaterials for tumor therapy: autophagy, apoptosis, and photothermal ablation.Journal of nanobiotechnology · 2021Review
- Recent Advances and Implication of Bioengineered Nanomaterials in Cancer Theranostics.Medicina (Kaunas, Lithuania) · 2021Review
- Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems.Biomolecules · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Autophagy is a conserved process that is critical for sequestering and degrading proteins, damaged or aged organelles, and for maintaining cellular homeostasis under stress conditions. Despite its dichotomous role in health and diseases, autophagy usually promotes growth and progression of advanced cancers. In this context, clinical trials using chloroquine and hydroxychloroquine as autophagy inhibitors have suggested that autophagy inhibition is a promising approach for treating advanced malignancies and/or overcoming drug resistance of small molecule therapeutics (i.e., chemotherapy and molecularly targeted therapy). Efficient delivery of autophagy inhibitors may further enhance the therapeutic effect, reduce systemic toxicity, and prevent drug resistance. As such, nanocarriers-based drug delivery systems have several distinct advantages over free autophagy inhibitors that include increased circulation of the drugs, reduced off-target systemic toxicity, increased drug delivery efficiency, and increased solubility and stability of the encapsulated drugs. With their versatile drug encapsulation and surface-functionalization capabilities, nanocarriers can be engineered to deliver autophagy inhibitors to tumor sites in a context-specific and/or tissue-specific manner. This review focuses on the role of nanomaterials utilizing autophagy inhibitors for cancer therapy, with a focus on their applications in different cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.